F. Magnotti, A. Vitale, D. Rigante, O. Lucherini, R. Cimaz, I. Muscari, A. Granados Afonso de Faria, B. Frediani, M. Galeazzi, L. Cantarini
Research Center of Systemic Autoimmune and Autoinflammatory Diseases, Rheumatology Unit, Policlinico Le Scotte, University of Siena, Siena, Italy. email@example.com
2013 Vol.31, N°3 ,Suppl.77 - PI 0141, PF 0149
Free to view (click on article PDF icon to read the article)
Tumour necrosis factor-receptor associated periodic syndrome (TRAPS) is a rare autosomal dominant autoinflammatory disorder characterised by recurrent episodes of long-lasting fever and inflammation in different regions of the body, as musculo-skeletal system, skin, gastrointestinal tube, serosal membranes and eye. Inflammatory attacks usually start in the pediatric age with initial corticosteroid-responsiveness. Most reported cases of TRAPS involve patients of European ancestry and diagnosis can be formulated by the combination of genetic analysis and a compatible phenotype. Its prognosis is strictly dependent on the appearance of amyloidosis, secondary to uncontrolled relapsing inflammation. Thanks to a better understanding of its pathogenesis, the disease is now managed with anti-interleukin (IL)-1 antagonists, rather than corticosteroids or tumour necrosis factor (TNF) inhibitors. The aim of this review is to describe the current understanding and advances of TRAPS genetic basis, pathogenesis and management options by integrating the most recent data in the medical literature.
PMID: 23899820 [PubMed]
Received: 09/02/2013 - Accepted : 09/04/2013 - In Press: 24/07/2013 - Published: 09/09/2013